Plaintiffs lawyers suing over the breast cancer drug Taxotere filed motions this week to ensure that the first bellwether trial against Sanofi-Aventis U.S. LLC is not about them.
“Plaintiff anticipates that Sanofi may attempt to alienate the jury by converting the trial into a referendum on lawful practices by plaintiff attorneys,” wrote lead trial counsel Darin Schanker, of Denver’s Bachus & Schanker, and Rand Nolen, of Fleming, Nolen & Jez in Houston, in a motion filed ahead of a trial scheduled for Sept. 16.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]